Significant Accounting Polices - Additional Information (Details)						3 Months Ended	12 Months Ended
	Jan. 14, 2022 USD ($)	Oct. 12, 2021 USD ($)	Mar. 19, 2021 USD ($)	Jan. 25, 2021 USD ($)	Apr. 11, 2020 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) Segment	Dec. 31, 2020 USD ($)	Oct. 04, 2021 USD ($)
Schedule Of Significant Accounting Policies [Line Items]
Upfront nonrefundable payment				$ 1,000,000.0
Loan in principal amount				$ 4,000,000.0
Issuance and bore interest rate				6.00%
Reimbursement payment			$ 14,000,000.0
Collaboration Agreement Amount			25,000,000.0
Development payments			10,000,000.0
Deferred collaboration funding							$ 15,825,938
Cash in excess of FDIC insured limit							$ 12,500,000	$ 5,500,000
Expected term of stock option granted to employees and directors, average contractual term and vesting period							10 years
Impairment of in-process research and development								118,600
Uncertain tax positions, accruals							$ 0	0
Accruals for interest or penalties related to income tax matters							0	0
Forgiveness of PPP loan							$ 568,909
Number of operating segment | Segment							1
PPP Loan | JPMorgan Chase Bank, N.A
Schedule Of Significant Accounting Policies [Line Items]
CARES act of 2020 aid loan amount					$ 600,000
Forgiveness of PPP loan						$ 600,000
In-process Research and Development | Research and Development
Schedule Of Significant Accounting Policies [Line Items]
Impairment of in-process research and development								100,000
Accounts Payable and Accrued Expenses
Schedule Of Significant Accounting Policies [Line Items]
Preclinical or clinical study expense							$ 200,000	1,800,000
Cash and Cash Equivalents
Schedule Of Significant Accounting Policies [Line Items]
Investments in money market funds							12,200,000	$ 5,300,000
Maximum
Schedule Of Significant Accounting Policies [Line Items]
Cash, FDIC insured amount							250,000
Relief
Schedule Of Significant Accounting Policies [Line Items]
Non-cash reduction recognized in secured loan							4,000,000.0
Collaboration Agreement | Second Development Payment
Schedule Of Significant Accounting Policies [Line Items]
Receivables recognized							5,000,000.0
Deferred collaboration funding							24,500,000
Deferred collaboration funding, current							15,800,000
Noncurrent liability							8,800,000
Deferred collaboration funding, cash received							35,000,000.0
Revenue recognized							1,300,000
Offset to research and development expenses							5,800,000
Offset to general and administrative expenses							$ 3,400,000
Collaboration Agreement | Relief
Schedule Of Significant Accounting Policies [Line Items]
Cash payment received			10,000,000.0			$ 10,000,000.0
Reimbursement payment			14,000,000.0	$ 14,000,000.0
Repayment of outstanding balance of prior loan and interest			4,000,000.0	$ 4,000,000.0
Development and commercial launch costs			$ 20,000,000.0
Net profit split ratio based on territory			60.00%	60.00%
Percentage of royalty net sales received			15.00%	15.00%
Milestone payment to be received			$ 6,000,000.0	$ 6,000,000.0
Potential proceeds from development payments subject to new drug application									$ 10,000,000.0
Proceeds from first tranche of development payments subject to new drug application		$ 5,000,000.0
Percentage of development and commercialization services			60.00%
Percentage of payment net profit territory			60.00%
Upfront non-refundable payment received				1,000,000.0
Collaboration Agreement | Relief | Maximum
Schedule Of Significant Accounting Policies [Line Items]
Development and commercial launch costs				20,000,000.0
Development payments				20,000,000.0
Collaboration Agreement | Relief | Second Development Payment
Schedule Of Significant Accounting Policies [Line Items]
Potential proceeds from development payments subject to new drug application									$ 10,000,000.0
Proceeds from first tranche of development payments subject to new drug application		5,000,000.0
Waiver and Agreement | Relief | Second Development Payment
Schedule Of Significant Accounting Policies [Line Items]
Proceeds from first tranche of development payments subject to new drug application	$ 5,000,000.0	$ 5,000,000.0
Proposed Collaboration and License Agreement
Schedule Of Significant Accounting Policies [Line Items]
Upfront non-refundable payment received			$ 1,000,000.0
Proposed Collaboration and License Agreement | Relief
Schedule Of Significant Accounting Policies [Line Items]
Upfront non-refundable payment received				$ 1,000,000.0